Great remote policy and PTO, but burnout, bureaucracy, and lack of hiring make it hard to stay - werkgeversreview Scientist bij Merck

3,0
29 jan 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Remote-first culture with solid remote work infrastructure. 25 days PTO is a real benefit and better than many competitors. Some smart and supportive teammates.

Minpunten

The organization is very bureaucratic – multiple layers of approval and endless internal processes slow everything down. As the company gets closer to the patent cliff, work-life balance has clearly worsened. Workload has increased, but support or headcount has not. Teams are understaffed, yet management prioritizes cost-cutting over hiring. There’s a constant expectation to do more without additional resources. Promotions feel rare and unclear. It’s hard to understand what you need to do to move up, and decisions often feel political rather than merit-based. There’s a strong “average” culture where people who contribute a lot and those who do the minimum are treated similarly. This makes it hard to stay motivated, and burnout is very real.

Ontdek andere reviews over Merck

5,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Excellent company to work with.

Minpunten

No cons encountered so far

4,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Minpunten

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bekijk reviews op: Nuttig|Beoordeling|Datum|Alle